We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Ranbaxy Submits Fewer ANDAs Due to Compliance Issues
Ranbaxy Submits Fewer ANDAs Due to Compliance Issues
January 30, 2009
The FDA’s import alert for 30 generic drug products made at two Ranbaxy production facilities in India has spurred the company to expand its U.S. manufacturing operations and take an estimated $50.8 million expense against earnings in 2008.